Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)

Cystic Fibrosis Clinical Trial

— TRI-STAR  

Official title:

TRI-STAR: Initial and Chronic MRSA Infection in CF (TRanslational Investigation of STaph. Aureus Resistance)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02684422
• Other study ID #: 15-0636
• Status: Completed
• Start date: July 2015
• Est. completion date: December 2021

Study information

• Verified date: January 2022
• Source: University of North Carolina, Chapel Hill
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to examine features of MRSA that are associated with chronic MRSA infection and bacterial persistence despite IV antibiotic therapy. Subjects are asked to expectorate sputum and complete CF symptom diaries both at beginning and end of IV therapy.

Description:

This is an observational, translational study examined bacterial morphology and function pre- vs. post antibiotic therapy in patients with CF who experience a pulmonary exacerbation that requires IV antibiotics.

All clinical care is dictated by the treating physician(s).

Inclusion criteria:

1. Male or female with a confirmed diagnosis of CF (by sweat test and/or identification of 2 CF disease causing mutations).

2. Chronic infection with MRSA defined as having had MRSA positive respiratory cultures for > 1 year with > 50% of cultures being MRSA positive.

3. Being able to expectorate sputum on a consistent basis, i.e. also at the end of IV therapy 3A: starting April 2017 people with CF who cannot expectorate sputum can also participate if they will do two orapharyngeal swab cultures.

4. Having a pulmonary exacerbation defined for this protocol as the decision of the treating physician to start IV therapy in hospital or at home. Typically this occurs when there has been a >5% drop in FEV1 % predicted compared to the patient's baseline and increased respiratory symptoms.

1. NOTE: Patients who had oral or inhaled antibiotics with or without MRSA activity but failed i.e. are changed to IV antibiotics are allowed to participate.

Exclusion criteria:

1. Presence / infection with B. cepacia genomovar III (B. cenocepacia)

2. Subjects who have undergone lung or liver transplant in the past (NOTE: patients listed for transplant are eligible)

3. Concomitant participation and/or use of an investigational drug within 30 days of this study. Concomitant observational studies are allowed with TRI-STAR

Sputum collection:

The subject will be asked to expectorate a sputum into a sterile specimen cup solely for this study. This may be a second sample after giving one for the clinical laboratory at start of therapy. The subject will be asked for a repeat sputum sample for the study at end of therapy.

Time point definition: A) Start of therapy sample: up to 3 days prior and up to 36 hours after the first dose of anti-MRSA antibiotic. B) End of therapy: no earlier than 36 hours prior to the last dose and up to one week after completion.

Collection of clinical information: Clinical information to be collected include:

Demographics, age, CF genotype, anthropometrics; FEV1 FVC, FEF 25-75 in liter and % predicted per site specific reference values; all medications (routine and those started within 2 weeks and at time of admission/IV therapy).

CF daily Symptom score: Subject will be asked to complete the CF Symptom diary for the first and last 3 days of IV therapy. For subjects admitted to the hospital this will be administered by the RC for those at home the RC will call / e-mail them as reminder or do it with them per phone.

Spirometry at conclusion of therapy: Most patients have a follow-up clinic visit or are still in the hospital at time of completion of IV therapy and spirometry is part of routine clinical assessment. NOTE: Patients who would not have a clinic visit at end of therapy may be asked to return for spirometry and sputum sample solely for this study. If the subject agrees to this, reimbursement for travel will be allowed.

Laboratory Assays:

In vitro assays done on either banked isolates in Aim 1 or sputum samples / MRSA isolates from sputum include tests on bacterial fitness as growth under different conditions; antibiotic susceptibility assays; metabolic and virulence activity and genes, and mutator rates for sputum isolates. More details are provided in the grant application.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: December 2021
• Est. primary completion date: October 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 99 Years

Eligibility

Inclusion Criteria:

1. Male or female with a confirmed diagnosis of CF (clinical features and positive sweat test and/or identification of 2 CF disease causing mutations).

2. At least 4 years of age or older.

3. Chronic infection with MRSA defined as having had MRSA positive respiratory cultures for > 1 year with = 50% of cultures being MRSA positive e.g. 2/4 of the most recent cultures grew MRSA.

4. Being able to expectorate sputum on a consistent basis, i.e. also at the end of IV therapy.

5. Having a pulmonary exacerbation defined for this protocol as the decision of the treating physician to start IV therapy in hospital or at home. Typically this occurs when there has been a >5% drop in FEV1 % predicted compared to the patient's baseline and increased respiratory symptoms.

NOTE: Patients who had oral or inhaled antibiotics with or without MRSA activity but failed this outpatient therapy i.e. are changed to IV anti-MRSA antibiotics are allowed to participate.(Example: was on oral doxycycline and on admission changed to ceftaroline = eligible. On oral doxycycline that is continued on admission = not eligible).

• Patient enrollment should be prioritized to those receiving IV vancomycin or ceftaroline, with secondary consideration of patients who receive oral anti-MRSA therapy (TMP-SMX or a tetracycline derivative) that was initiated on hospital admission.

• Patients on linezolid will not be included as this medication is given orally and IV and may confound analyses.

Exclusion Criteria:

1. Presence / infection with B. cepacia genomovar III (=B. cenocepacia). Subjects who have undergone lung or liver transplant in the past (NOTE: patients listed for transplant are eligible)

2. Concomitant participation and/or use of an investigational drug within 30 days of this study.

3. Concomitant observational studies are allowed with TRI-STAR, if approved by the other study investigator or their proxy.

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis
• Methicillin-Resistant Staphylococcus Aureus
• Staphylococcal Infections

Intervention

Other:
• Intervention N/A. Observational study
There are no interventions to the subjects other than collection of an expectorated sputum since this is an observational study; There are no study groups.See details per detailed study description.

Locations

Country	Name	City	State
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina
United States	University of Washington	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
University of North Carolina, Chapel Hill

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in presence of hypermutable MRSA isolates post-therapy compared to pre-therapy.		2-3 weeks (course of IV antibiotics as determined by clinician)
Secondary	Other MRSA characteristics in sputum	In vitro measures of MRSA fitness, antimicrobial susceptibilities, biofilm formation and exploratory in vitro bacterial assays.	2 weeks (course of IV antibiotics)
Secondary	Clinical improvement with therapy	These measures for clinical improvement will be lung function and CF specific quality of life questionnaires.	2-3 weeks (course of IV antibiotics)